Link to article

[Phantasia]

This looks interesting-

prnewswire.com/news-release...

Very early days but looks hopeful.

[EPguy]

This was designed for solid tumors. But they found an adverse event in lowered PLT count

It is specific to this effect and for MPNs this bug is a feature. They made the connection:

"the on-target dose/exposure-proportional decrease in platelet constitute a proof-of-principle that JBI-802 can be an active compound in hematological malignancies like Essential Thrombocythemia (ET)". They are planning trials.

There is a need for a PLT specific agent, Bomedemstat in its long trials is the only other new one.

It will be interesting whether it has any influence on the mutation.

[Spanelmad in reply to EPguy]

Thank you for debunking the medical!!!